Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / France

Marie Skłodowska-Curie Action · Running

CombGeneTher Gene-Independent Combination Therapy for Rod-Cone Dystrophy

Coordinator
Sorbonne Universite, France
Runs
1 September 2023 to 31 August 2025
Status
Running
EU funding
€212k
Total cost
—
Partners
1 organisations in 1 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101065402

What the project is doing

In the project's own words, from its summary on CORDIS.

Rod-cone dystrophies are inherited retinal diseases whose clinical course begin with the degeneration of rod photoreceptors and evolve with the progressive loss of cones that, in turn, leads to complete blindness. These diseases affect 1:2500 individuals worldwide with many underlying gene defects. Although gene replacement therapy has been very successful in treating inherited retinal degenerations in the clinic, with one FDA approved product on the market and over 30 clinical trials, it is costly and time consuming to develop a gene replacement therapy for each mutation.

Moreover, gene replacement can only be helpful if the underlying mutation is known and recessive. Despite the genetic heterogeneity of these diseases as well as their inherent complexity, all rod-cone dystrophies converge on a common phenotype of rod cell loss, followed by cone cell degeneration first in the periphery and then in the fovea, leading to complete blindness. A gene therapy approach aiming to counteract the symptoms of rod-cone dystrophy rather than the individual genetic causes has the potential to be helpful in the highest number of affected patients.

In this action we propose to develop a combination gene therapy to restore light sensitivity in mouse models of rod-cone dystrophies. AAV-mediated expression of optogenetic channels in cone photoreceptors will restore light sensitivity and maintain downstream retinal circuitry processing. The optogenetic therapy will be combined with the AAV-mediated delivery of rod derived cone viability factor (RdCVF), a factor normally secreted by rods to promote cone survival, lost in rod-cone dystrophies; RdCVF expression in combination with optogenetic channel expression will promote survival of newly lightsensitive cones.

Furthermore, this action proposes to deliver optogenetic channels and RdCVF to human retinal organoids, showing expression and photoreceptor activation in human tissue in vitro.

Topics

Who is involved

OrganisationCityCountryRole
Sorbonne UniversiteParisFranceCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI